{
    "clinical_study": {
        "@rank": "87594", 
        "brief_summary": {
            "textblock": "OBJECTIVES: I.  Determine the response rate and response duration to rituximab in patients\n      with immune thrombocytopenic purpura.\n\n      II.  Evaluate the toxicity associated with this treatment regimen in these patients.\n\n      III.  Evaluate the alteration in antiplatelet antibody with this treatment regimen in these\n      patients."
        }, 
        "brief_title": "Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura", 
        "condition": "Purpura, Thrombocytopenic, Idiopathic", 
        "condition_browse": {
            "mesh_term": [
                "Purpura", 
                "Purpura, Thrombocytopenic", 
                "Purpura, Thrombocytopenic, Idiopathic"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: Patients receive rituximab IV on days 1, 8, 15, and 22.  Patients who\n      achieve a clinical response lasting over 4 months may receive a second course of rituximab.\n\n      Patients are followed at 5, 6, 8, and 12 weeks, and then at 6 and 9 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n        Clinically confirmed immune thrombocytopenic purpura (ITP) Platelet count less than\n        75,000/mm3 on two occasions at least 1 week apart within past month\n\n        Normal to increased numbers of megakaryocytes on bone marrow examination within past 6\n        months\n\n        Failed prior steroid therapy (i.e., unable to achieve sustained platelet count greater\n        than 75,000/mm3)\n\n        No drug associated ITP\n\n        No B cell malignancies\n\n        No evidence of disseminated intravascular coagulation (DIC)\n\n        --Prior/Concurrent Therapy--\n\n        Endocrine therapy: Concurrent steroids allowed as long as platelet count is less than\n        75,000/mm3 and dose is not changed within past 2 weeks or during study\n\n        Other:\n\n          -  No other concurrent medical therapy for immune thrombocytopenia purpura (ITP)\n\n          -  At least 2 weeks since prior therapy for ITP (except steroids)\n\n          -  At least 4 weeks since prior cyclosporine\n\n        --Patient Characteristics--\n\n        Performance status: ECOG 0-2\n\n        Life expectancy: At least 6 months\n\n        Renal: Creatinine no greater than 2.0 mg/dL\n\n        Cardiovascular: No congestive heart failure or symptomatic coronary insufficiency\n\n        Other:\n\n          -  No clinically significant bleeding (i.e., other than mild mucosal bleeding or\n             petechiae)\n\n          -  No sepsis or fever\n\n          -  No active infection requiring therapy\n\n          -  No active chronic viral infection\n\n          -  HIV negative\n\n          -  No other concurrent or prior malignancy within past 5 years except squamous or basal\n             cell carcinoma of the skin or carcinoma in situ of the cervix\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "20", 
        "firstreceived_date": "May 2, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00005652", 
            "org_study_id": "199/15038", 
            "secondary_id": [
                "UAB-9866", 
                "UAB-BB-IND-8136", 
                "UAB-F990224001"
            ]
        }, 
        "intervention": {
            "intervention_name": "rituximab", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Rituximab"
        }, 
        "keyword": [
            "hematologic disorders", 
            "immune thrombocytopenic purpura", 
            "rare disease"
        ], 
        "lastchanged_date": "September 8, 2008", 
        "location": {
            "facility": {
                "address": {
                    "city": "Birmingham", 
                    "country": "United States", 
                    "state": "Alabama", 
                    "zip": "35294"
                }, 
                "name": "University of Alabama Comprehensive Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "overall_official": {
            "affiliation": "University of Alabama at Birmingham", 
            "last_name": "Mansoor Noorali Saleh", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Unspecified"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2007", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00005652"
        }, 
        "source": "Office of Rare Diseases (ORD)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Alabama at Birmingham", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2000", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2008"
    }, 
    "geocoordinates": {
        "University of Alabama Comprehensive Cancer Center": "33.521 -86.802"
    }
}